Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD07387
- Development stage
- Phase 2
- Lead developer
- Galderma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CD07387 is a small molecule Janus kinase 1 (JAK1) inhibitor developed by Galderma for the topical treatment of vitiligo. Vitiligo is an autoimmune skin condition characterized by the loss of melanocytes, leading to depigmented patches of skin. The pathogenesis of vitiligo involves the IFN-γ/STAT1 signaling pathway, which drives the production of CXCL10 by keratinocytes, subsequently recruiting autoreactive T cells that destroy melanocytes. By selectively inhibiting JAK1, CD07387 aims to disrupt this inflammatory loop, potentially allowing for melanocyte repopulation and skin repigmentation. The compound is formulated as a topical solution and has been evaluated in Phase 2 clinical trials to assess its safety, local tolerability, and pharmacodynamic effects in patients with vitiligo.
02
Targets
Beyond the preview
Go deeper on CD07387.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD07387.